西妥昔单抗联合紫杉醇对人鼻咽癌CNE-1细胞抑制作用及其分子机制研究
发布时间：2018-10-17 07:08
【摘要】：目的：本研究以人鼻咽癌CNE-1细胞为研究对象，探讨西妥昔单抗（Cetuximab）联合紫杉醇（Paclitaxel，PTX）对其增殖及凋亡的影响，并进一步研究其可能的分子机制。 方法：培养人鼻咽癌CNE-1细胞株，随机将细胞分为空白对照组、紫杉醇组、西妥昔单抗组和联合用药组。用MTT法检测细胞抑制率，流式细胞术检测细胞凋亡率，实时荧光定量PCR （RT-PCR法）及Western-blot法检测EGFR、MMP-2的mRNA和蛋白表达。 结果：联合用药组的细胞抑制率高于紫杉醇组和西妥昔单抗组（P值分别为0.002、0.000）；联合用药组的细胞凋亡率高于紫杉醇组和西妥昔单抗组（P值均为0.000）；联合用药组的EGFR、MMP-2的mRNA表达值均低于紫杉醇组和西妥昔单抗组（各组间EGFR mRNA的表达P值分别为0.000、0.001；MMP-2mRNA的表达P值均为0.000）；联合用药组的EGFR、MMP-2的蛋白值表达均低于紫杉醇组和西妥昔单抗组（各组间EGFR蛋白的表达P值均为0.000；MMP-2蛋白的表达P值分别为为0.000、0.006）。 结论：西妥昔单抗联合紫杉醇能够抑制人鼻咽癌CNE-1细胞的增殖，，促进其凋亡，两者联用具有协同作用，其分子机制可能是通过抑制肿瘤细胞EGFR、MMP-2的表达来实现。
[Abstract]:Aim: to investigate the effects of cetuximab (Cetuximab) combined with paclitaxel (Paclitaxel,PTX) on the proliferation and apoptosis of human nasopharyngeal carcinoma (NPC) CNE-1 cells and to further study its molecular mechanism. Methods: human nasopharyngeal carcinoma (NPC) CNE-1 cell lines were cultured and randomly divided into three groups: blank control group, paclitaxel group, cetuximab group and combination therapy group. Cell inhibition rate was detected by MTT assay, apoptosis rate was detected by flow cytometry, mRNA and protein expression of EGFR,MMP-2 were detected by real-time fluorescence quantitative PCR (RT-PCR) and Western-blot assay. Results: the cell inhibition rate in combination group was higher than that in paclitaxel group and cetuximab group (P = 0.002 + 0.000), the apoptosis rate in combination group was higher than that in paclitaxel group and cetuximab group (P = 0.000). The mRNA expression of EGFR,MMP-2 in combination group was lower than that in paclitaxel group and cetuximab group (P = 0.0000.0001MP-2, P = 0.000). The expression of EGFR,MMP-2 protein in combination group was lower than that in paclitaxel group and cetuximab group (P value of 0.000mmp2protein was 0.000,0.006, respectively). Conclusion: cetuximab combined with paclitaxel can inhibit the proliferation and promote the apoptosis of human nasopharyngeal carcinoma (NPC) CNE-1 cells. The molecular mechanism of the combination of cetuximab and paclitaxel may be by inhibiting the expression of EGFR,MMP-2 in human nasopharyngeal carcinoma cells.
【学位授予单位】：重庆医科大学
【学位级别】：硕士
【学位授予年份】：2014
【分类号】：R734.2
本文编号：2275920
[Abstract]:Aim: to investigate the effects of cetuximab (Cetuximab) combined with paclitaxel (Paclitaxel,PTX) on the proliferation and apoptosis of human nasopharyngeal carcinoma (NPC) CNE-1 cells and to further study its molecular mechanism. Methods: human nasopharyngeal carcinoma (NPC) CNE-1 cell lines were cultured and randomly divided into three groups: blank control group, paclitaxel group, cetuximab group and combination therapy group. Cell inhibition rate was detected by MTT assay, apoptosis rate was detected by flow cytometry, mRNA and protein expression of EGFR,MMP-2 were detected by real-time fluorescence quantitative PCR (RT-PCR) and Western-blot assay. Results: the cell inhibition rate in combination group was higher than that in paclitaxel group and cetuximab group (P = 0.002 + 0.000), the apoptosis rate in combination group was higher than that in paclitaxel group and cetuximab group (P = 0.000). The mRNA expression of EGFR,MMP-2 in combination group was lower than that in paclitaxel group and cetuximab group (P = 0.0000.0001MP-2, P = 0.000). The expression of EGFR,MMP-2 protein in combination group was lower than that in paclitaxel group and cetuximab group (P value of 0.000mmp2protein was 0.000,0.006, respectively). Conclusion: cetuximab combined with paclitaxel can inhibit the proliferation and promote the apoptosis of human nasopharyngeal carcinoma (NPC) CNE-1 cells. The molecular mechanism of the combination of cetuximab and paclitaxel may be by inhibiting the expression of EGFR,MMP-2 in human nasopharyngeal carcinoma cells.
【学位授予单位】：重庆医科大学
【学位级别】：硕士
【学位授予年份】：2014
【分类号】：R734.2
【参考文献】
相关期刊论文 前1条
1 ;索拉非尼治疗晚期及转移性头颈部鳞癌的临床Ⅱ期研究评价[J];中国口腔颌面外科杂志;2010年05期
本文编号：2275920
本文链接：https://www.wllwen.com/yixuelunwen/yank/2275920.html
最近更新
教材专著
